Cargando…
Diabetes: how to manage cardiovascular risk in secondary prevention patients
Atherosclerotic cardiovascular disease (ASCVD) commonly affects people with type 2 diabetes (T2D). Historically, traditional cardiovascular (CV) risk-lowering therapies in patients with T2D and ASCVD have included antiplatelet agents, blood pressure-lowering therapies, lipid-lowering therapies and h...
Autores principales: | Anderson, Sarah L, Marrs, Joel C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioExcel Publishing Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9205572/ https://www.ncbi.nlm.nih.gov/pubmed/35775074 http://dx.doi.org/10.7573/dic.2021-10-1 |
Ejemplares similares
-
Antihyperglycemic Medications and Cardiovascular Risk Reduction
por: Anderson, Sarah L, et al.
Publicado: (2017) -
Tirzepatide for type 2 diabetes
por: Anderson, Sarah L, et al.
Publicado: (2023) -
Ertugliflozin in the treatment of type 2 diabetes mellitus
por: Marrs, Joel C, et al.
Publicado: (2020) -
A Review of the Role of the Pharmacist in Heart Failure Transition of Care
por: Anderson, Sarah L., et al.
Publicado: (2018) -
Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment
por: Anderson, Sarah L, et al.
Publicado: (2018)